Our new podcast explores trends in #tardive #dyskinesia diagnosis and use of #VMAT2 inhibitors among adults treated with #antipsychotics. The study finds #TD remains underdiagnosed and treatment rates remain low.

🎧Listen: jcpjournal.libsyn.com/the-use-of-v...
📜Read: journals.lww.com/psychopharma...

In a new article published in FEBS Letters, Pei Tong et al. describe the use of an amphipol-stabilized multi-pass #transmembraneprotein as an immunogen to generate high-affinity #antibodies against #VMAT2.
Online here ➡️ doi.org/10.1002/1873...

New Insights into VMAT2 Use for Child Movement Disorders VMAT2 inhibitors improve symptoms in many children with movement disorders, but insurance denials and affordability remain major barriers to treatment access and continuation.

💡New insights into VMAT2 inhibitors offer hope for children with movement disorders. Experts urge caution on timing and safety.

#AMJNeurology #VMAT2 #Tics

Read the story: www.emjreviews.com/en-us/amj/ne...